Annual Cash & Cash Equivalents
$755.13 M
+$30.60 M+4.22%
31 December 2023
Summary:
BioMarin Pharmaceutical annual cash & cash equivalents is currently $755.13 million, with the most recent change of +$30.60 million (+4.22%) on 31 December 2023. During the last 3 years, it has risen by +$105.97 million (+16.32%). BMRN annual cash & cash equivalents is now -13.75% below its all-time high of $875.49 million, reached on 31 December 2014.BMRN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$675.45 M
-$296.70 M-30.52%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly cash and cash equivalents is currently $675.45 million, with the most recent change of -$296.70 million (-30.52%) on 30 September 2024. Over the past year, it has dropped by -$109.97 million (-14.00%). BMRN quarterly cash and cash equivalents is now -33.50% below its all-time high of $1.02 billion, reached on 30 September 2020.BMRN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.2% | -14.0% |
| 3 y3 years | +16.3% | +9.4% |
| 5 y5 years | +52.9% | +59.6% |
BMRN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +28.6% | -30.5% | +16.4% |
| 5 y | 5 years | at high | +72.6% | -33.5% | +59.6% |
| alltime | all time | -13.8% | +7933.3% | -33.5% | >+9999.0% |
BioMarin Pharmaceutical Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $675.45 M(-30.5%) |
| June 2024 | - | $972.15 M(+30.1%) |
| Mar 2024 | - | $747.00 M(-1.1%) |
| Dec 2023 | $755.13 M(+4.2%) | $755.13 M(-3.9%) |
| Sept 2023 | - | $785.41 M(+13.1%) |
| June 2023 | - | $694.38 M(+19.7%) |
| Mar 2023 | - | $580.07 M(-19.9%) |
| Dec 2022 | $724.53 M(+23.4%) | $724.53 M(-4.9%) |
| Sept 2022 | - | $761.51 M(+22.9%) |
| June 2022 | - | $619.80 M(+2.4%) |
| Mar 2022 | - | $605.44 M(+3.1%) |
| Dec 2021 | $587.28 M(-9.5%) | $587.28 M(-4.8%) |
| Sept 2021 | - | $617.14 M(-3.8%) |
| June 2021 | - | $641.53 M(-3.9%) |
| Mar 2021 | - | $667.31 M(+2.8%) |
| Dec 2020 | $649.16 M(+48.4%) | $649.16 M(-36.1%) |
| Sept 2020 | - | $1.02 B(+24.0%) |
| June 2020 | - | $818.90 M(+71.8%) |
| Mar 2020 | - | $476.63 M(+9.0%) |
| Dec 2019 | $437.45 M(-11.4%) | $437.45 M(+3.4%) |
| Sept 2019 | - | $423.22 M(+37.6%) |
| June 2019 | - | $307.58 M(-15.6%) |
| Mar 2019 | - | $364.37 M(-26.2%) |
| Dec 2018 | $493.98 M(-17.4%) | $493.98 M(-44.0%) |
| Sept 2018 | - | $882.18 M(+106.4%) |
| June 2018 | - | $427.41 M(-9.8%) |
| Mar 2018 | - | $473.98 M(-20.7%) |
| Dec 2017 | $598.03 M(+46.5%) | $598.03 M(+38.6%) |
| Sept 2017 | - | $431.40 M(+21.6%) |
| June 2017 | - | $354.86 M(+1.9%) |
| Mar 2017 | - | $348.23 M(-14.7%) |
| Dec 2016 | $408.33 M(+2.8%) | $408.33 M(-42.3%) |
| Sept 2016 | - | $707.35 M(+131.2%) |
| June 2016 | - | $305.97 M(+13.1%) |
| Mar 2016 | - | $270.45 M(-31.9%) |
| Dec 2015 | $397.04 M(-54.6%) | $397.04 M(+5.5%) |
| Sept 2015 | - | $376.35 M(-14.6%) |
| June 2015 | - | $440.66 M(-51.1%) |
| Mar 2015 | - | $900.57 M(+2.9%) |
| Dec 2014 | $875.49 M(+53.9%) | $875.49 M(+120.0%) |
| Sept 2014 | - | $398.00 M(-31.9%) |
| June 2014 | - | $584.72 M(-8.6%) |
| Mar 2014 | - | $639.78 M(+12.5%) |
| Dec 2013 | $568.78 M(+215.1%) | $568.78 M(+213.3%) |
| Sept 2013 | - | $181.56 M(+3.5%) |
| June 2013 | - | $175.44 M(+13.6%) |
| Mar 2013 | - | $154.38 M(-14.5%) |
| Dec 2012 | $180.53 M(+290.1%) | $180.53 M(-0.4%) |
| Sept 2012 | - | $181.33 M(+2.0%) |
| June 2012 | - | $177.76 M(+115.2%) |
| Mar 2012 | - | $82.59 M(+78.5%) |
| Dec 2011 | $46.27 M | $46.27 M(-35.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $71.25 M(-36.9%) |
| June 2011 | - | $112.96 M(+24.4%) |
| Mar 2011 | - | $90.78 M(+3.1%) |
| Dec 2010 | $88.08 M(-47.3%) | $88.08 M(-30.9%) |
| Sept 2010 | - | $127.54 M(+10.2%) |
| June 2010 | - | $115.78 M(+6.3%) |
| Mar 2010 | - | $108.96 M(-34.8%) |
| Dec 2009 | $167.17 M(-25.0%) | $167.17 M(-12.8%) |
| Sept 2009 | - | $191.78 M(-4.1%) |
| June 2009 | - | $200.05 M(-6.8%) |
| Mar 2009 | - | $214.58 M(-3.7%) |
| Dec 2008 | $222.90 M(-2.4%) | $222.90 M(-17.8%) |
| Sept 2008 | - | $271.22 M(+7.5%) |
| June 2008 | - | $252.21 M(-21.2%) |
| Mar 2008 | - | $319.99 M(+40.1%) |
| Dec 2007 | $228.34 M(+156.1%) | $228.34 M(-21.8%) |
| Sept 2007 | - | $291.82 M(+42.3%) |
| June 2007 | - | $205.01 M(+108.5%) |
| Mar 2007 | - | $98.33 M(+10.3%) |
| Dec 2006 | $89.16 M(+134.1%) | $89.16 M(-53.5%) |
| Sept 2006 | - | $191.78 M(-32.9%) |
| June 2006 | - | $285.99 M(-16.3%) |
| Mar 2006 | - | $341.69 M(+797.0%) |
| Dec 2005 | $38.09 M(+191.2%) | $38.09 M(-32.2%) |
| Sept 2005 | - | $56.21 M(+228.5%) |
| June 2005 | - | $17.11 M(+52.2%) |
| Mar 2005 | - | $11.25 M(-14.0%) |
| Dec 2004 | $13.08 M(-89.2%) | $13.08 M(-62.6%) |
| Sept 2004 | - | $34.98 M(-27.5%) |
| June 2004 | - | $48.25 M(-49.8%) |
| Mar 2004 | - | $96.20 M(-20.8%) |
| Dec 2003 | $121.41 M(+260.9%) | $121.41 M(-35.4%) |
| Sept 2003 | - | $187.98 M(-15.2%) |
| June 2003 | - | $221.77 M(+76.2%) |
| Mar 2003 | - | $125.83 M(+274.1%) |
| Dec 2002 | $33.64 M(+168.5%) | $33.64 M(+3.8%) |
| Sept 2002 | - | $32.41 M(+67.4%) |
| June 2002 | - | $19.36 M(+6.4%) |
| Mar 2002 | - | $18.20 M(+45.3%) |
| Dec 2001 | $12.53 M(-24.2%) | $12.53 M(+73.3%) |
| Sept 2001 | - | $7.23 M(-61.9%) |
| June 2001 | - | $18.97 M(-3.8%) |
| Mar 2001 | - | $19.72 M(+19.3%) |
| Dec 2000 | $16.53 M(-29.4%) | $16.53 M(+2.7%) |
| Sept 2000 | - | $16.10 M(+51.7%) |
| June 2000 | - | $10.61 M(-73.9%) |
| Mar 2000 | - | $40.67 M(+73.7%) |
| Dec 1999 | $23.41 M(+149.1%) | $23.41 M(-28.2%) |
| Sept 1999 | - | $32.60 M(+89.5%) |
| June 1999 | - | $17.20 M(+377.8%) |
| Mar 1999 | - | $3.60 M |
| Dec 1998 | $9.40 M | - |
FAQ
- What is BioMarin Pharmaceutical annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual cash & cash equivalents year-on-year change?
- What is BioMarin Pharmaceutical quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly cash and cash equivalents year-on-year change?
What is BioMarin Pharmaceutical annual cash & cash equivalents?
The current annual cash & cash equivalents of BMRN is $755.13 M
What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual cash & cash equivalents is $875.49 M
What is BioMarin Pharmaceutical annual cash & cash equivalents year-on-year change?
Over the past year, BMRN annual cash & cash equivalents has changed by +$30.60 M (+4.22%)
What is BioMarin Pharmaceutical quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BMRN is $675.45 M
What is the all time high quarterly cash and cash equivalents for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly cash and cash equivalents is $1.02 B
What is BioMarin Pharmaceutical quarterly cash and cash equivalents year-on-year change?
Over the past year, BMRN quarterly cash and cash equivalents has changed by -$109.97 M (-14.00%)